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Background: To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, 
travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, 
Germany, and Sweden).
Methods: Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy 
in each of the 4 countries. Drops were weighed by a single operator at 1 site according to 
standardized procedures. Residual drops were then counted. Unit bottle costs were estimated 
from tariff lists. Eye-drop weights were entered into a nested analysis of variance comprising 
drug, instillation day, country, the interaction, and a sample factor nested within the country 
factor. Effectiveness was represented by treatment failure rates estimated from a meta-analysis 
and a general practitioner survey.
Results: Every drug bottle contained sufficient drops to treat 1 patient for 28/31 days. Drop-size 
heterogeneity between countries was observed for bimatoprost and bimatoprost/timolol. Mean 
travoprost and travoprost/timolol drop-sizes were the smallest, and drop-counts per bottle were 
the lowest for latanoprost, or latanoprost/timolol. In all 4 countries annual costs were least for 
travoprost and travoprost/timolol.
Conclusions: On taking into account drug costs and effectiveness, travoprost and travoprost/
timolol were cheaper and more effective than latanoprost and latanoprost/timolol and were 
cheaper than bimatoprost and bimatoprost/timolol.
Keywords: prostaglandin analogue, economics, daily cost
Introduction
Glaucoma prevalence in industrialized countries ranges from 1% to 3% and constitutes 
a major cause of irreversible blindness worldwide.1 Its most common form in adults is 
primary open-angle glaucoma (POAG), which is associated with increased intraocular 
pressure (IOP) and leads to progressive visual field loss.2 To preserve visual function, 
it is essential to prevent optic nerve damage by decreasing intraocular hypertension.
First-line treatment in POAG aims at reducing IOP, usually with one of the 
following three prostaglandin analogues (PGAs): latanoprost 0.005% (Xalatan®; Pfizer 
Inc., New York, NY, USA), travoprost 0.004% (Travatan®; Alcon Inc., Fort Worth, 
Texas, USA), and bimatoprost 0.03% (Lumigan®; Allergan Inc., Irvine, CA, USA). 
When any of these single agents fails to control IOP sufficiently it is customary to add 
a beta-blocker, often in a fixed combination. Various fixed combinations have recently 
become available, eg, bimatoprost 0.03%/timolol (Ganfort®; Allergan Inc., Irvine, CA, 
USA), latanoprost 0.005%/timolol (Xalacom®; Pfizer Inc, New York, NY, USA), and 
travoprost 0.004%/timolol (DuoTrav®; Alcon Inc., Fort Worth, Texas, USA).Clinical Ophthalmology 2009:3 472
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Optimization of expenditure on medical resources 
first depends on evaluating efficacy and safety data, but 
subsequently extends to disease costs and, in particular, 
treatment costs. Several clinical trials have directly compared 
the aforementioned PGAs, in monotherapy and in fixed 
combinations with timolol.3–18 A meta-analysis by Denis 
et al19 found that IOP was better controlled (1 mmHg, approx) 
by travoprost or bimatoprost than by latanoprost, ie, the 
incidence rate ratio (IRR) of IOPs  18 mmHg was 1.17 
(1.00; 1.35) higher with latanoprost.
Treatment costs are important not only to health 
authorities but also to general practitioners responsible for 
their drug budgets, as in Germany. Several studies have 
focussed on glaucoma drug costs, using various methods and 
economic indicators (eg, costs per mmHg decrease; costs to 
attain a 20% IOP decrease).20–24 The number of eye-drops in 
a bottle (drop-count) is also a major item when estimating 
daily treatment costs, as the drop-count fixes the number of 
treatment days delivered per bottle.
According to the study conducted by Frankel in the 
United States, bimatoprost 0.03% had the lowest monthly and 
annual costs and the greatest cost effectiveness for lowering 
IOP compared with latanoprost 0.005% and travoprost 
0.004%. The savings came from more drops in a bimatoprost 
bottle (113 for bimatoprost 0.03%, 84 for latanoprost 0.005%, 
and 83 for travoprost 0.004%), resulting in longer treatment 
duration per bottle. Cost effectiveness was based on an 
average cost per mmHg reduction IOP.
The aim of this manuscript was to check whether the above 
results would apply to 4 selected EU countries. This study 
compares the daily and annual treatment costs associated with 
various first-line and second-line treatments for patients with 
glaucoma or IOP in several European countries.
Methods
The study included 4 European countries: Denmark, Finland, 
Germany, and Sweden. Three first-line, single agents for 
IOP control were compared, ie, bimatoprost 0.03% (BP), 
latanoprost 0.005% (LP), and travoprost 0.004% (TP). Simi-
larly, 3 fixed-combination agents for second-line therapy were 
compared, ie, bimatoprost 0.03%/timolol (BP/T), latanoprost 
0.005%/timolol (LP/T), and travoprost 0.004%/timolol (TP/T).
Drop-count estimate
Each of the 6 glaucoma treatments was sampled by buying 
5 new eye-drop bottles (4 bottles of travoprost 0.004% in 
Finland, only) from 1 suburban pharmacist in each of the 
4 countries. All bottles had similar expiry dates and all 
were sent to the US for centralized drop-count and drop-size 
evaluations, performed by a single assessor in order to reduce 
measurement variability.
Measurement methods followed standard operating 
procedures. Bottles were numbered sequentially and all outer 
encumbrances were removed (eg, shrink bands and obvious 
closure rings). Each container was weighed and its dispensing 
angle for drop expression was specified and recorded. 
A weigh boat, or suitable container, was centered on the 
balance pan and tared. A sample bottle was selected and 
shaken, as appropriate, before removing the cap. Any 
overflow was recorded before the bottle was held above the 
weigh boat, at the desired angle from horizontal, and finally 
1 drop was dispensed into the weigh boat. The bottle number 
and drop weight (‘drop-size’ to the nearest 0.0001 g, 0.1 mg) 
were recorded. The sequence was repeated for the second 
drop. The cap was then replaced and the bottle stored upright 
for reweighing on subsequent days.
According to the relevant Summaries of Product 
Characteristics,25 shelf-life after bottle opening ranged 
from 28 to 31 days, depending on the product and country. 
Hence a maximum of 62 measurements were performed, 
as above, on every bottle of all 6 drugs purchased in each 
of the 4 countries, to represent patients’ daily instillations. 
On the day when the last of 62 weighings was completed, 
the procedure continued until the bottle was empty in order 
to measure the total fill of each bottle and, in due course, 
estimate the average number of drops in a bottle and total 
fill (sum of drop weights). The percentage of total product 
remaining in each bottle, after 62 weighings were completed, 
was also estimated and averaged. Observations were averaged 
for the total fill in grams (SD; range), drop-size in milligrams 
(SD; range), and total drop-count per bottle (SD; range).
Treatment cost estimation
Treatment costs, expressed as euros (2008), were estimated 
for each country and agent in terms of average drop count and 
local retail price. Annual and daily costs were calculated for 
each agent and country, based on local public prices26–29 and 
treatment durations of 28 and 31 days per month, as specified 
in the Summary of Product Characteristics of the country 
concerned.
statistical analysis
The statistical analysis was performed with SAS software 
(SAS Institute, North Carolina, USA) Release No. 9.1. 
All statistical tests were interpreted two-sided with alpha 
fixed at 5%.Clinical Ophthalmology 2009:3 473
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Drop-sizes (mg) for the first 62 drops per bottle of each 
agent were analyzed in order to evaluate experimental 
reliability, and drop-size variability was estimated across 
instillation days and between countries for each agent.
A nested analysis of variance was conducted separately 
for each agent comprising ‘day’ and ‘country’ factors treated 
as fixed effects, their possible interaction, and a ‘sample 
factor’ nested within the ‘country factor’. Except for 1 missing 
sample (Finland: travoprost 0.004%) the design was fully 
balanced. Homoscedasticity and normality of the residues 
were checked. Graphs plotted the average daily drop-size 
evolution per agent for individual countries, or overall, 
according to observed statistical significances. Stepwise 
regression analyses determined effects and the best-fitting 
trend generated by linear, quadratic, and cubic models.
Results
The daily evolution of average drop-sizes over 1 month is 
shown in Figures 1 to 3 for monotherapy and Figures 4 to 6 for 
fixed combination agents. Statistically significant differences 
in drop-size were observed across simulated instillation days 
with all agents in all 4 countries. In particular, both the LP 
(Figure 2) and LP/T (Figure 5) curves differ from those of 
alternative agents by decreases of average drop-size over 
time. The TP (Figure 3) and TP/T (Figure 6) curves show 
slight fluctuations about steady average drop-sizes.
Significant differences between countries were observed 
with BP and BP/T. The BP curve for Denmark indicates a 
smaller mean drop-size during the first half of the month, 
compared to all other countries (Figure 1; P  0.0001). 
This is reflected in Table 1 where the mean drop-size was 
less than in all other countries, which were similar. The 
BP/T curve for Finland indicates smaller mean drop-sizes 
across the entire experimental period, especially in the first 
half of the month, compared to its curves in other countries 
(Figure 4; P  0.0001). This conforms to the mean drop-size 
in Table 1. Other BP/T trend differences between countries 
indicate increasing mean drop-sizes over time (high at the 
end of the month) for Denmark and Germany, and a slow 
biphasic trend for Sweden (decreasing at the start of the 
month, then rising).
Tables 2 to 9 present the mean total fill and drop-counts 
of all 6 agents (monotherapy and fixed combinations) per 
country. Drop-counts were highest for BP/T and decreased 
in the sequence LP/T  TP/T in all countries. The mean 
drop-count per bottle varied from 79 to 115 across all 
agents, but was always least with LP and LP/T. Given the 
number of drops required for 62 instillations over 31 days, 
the remaining ‘unused’ drops per bottle were least for LP 
and LP/T (+21% to +24%) in all countries. The percentage 
of remaining drops was highest for TP/T (+41% to +46%) 
in all countries, except Finland, and slightly less for BP and 
BP/T (+39% to +42%).
Annual and daily costs of glaucoma treatment were 
calculated for each country based on public retail prices 
(Tables 2 to 9). Annual costs (based on 28/31 days per month) 
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Figure 1 Bimatoprost 0.03%: daily average of drop size by country and trend fitting.Clinical Ophthalmology 2009:3 474
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of the three first-line monotherapy agents were higher for 
LP than BP ( 13/ 12) or TP ( 22/ 20) in Germany, and 
higher than BP ( 45/ 40) or TP ( 45/ 40) in Denmark. 
In Sweden, TP was cheaper than both BP and LP. For 
second-line fixed combinations, annual costs were more for 
LP/T than BP/T ( 46/ 41) or TP/T ( 46/ 41) in Sweden. 
Annual costs were also more for LP/T than BP/T ( 12/ 10) 
or TP/T ( 41/ 35) in Germany. In Finland LP/T and BP/T 
were equal in price, but cost more than TP/T ( 12/ 11). 
In Denmark BP/T cost more than both LP/T ( 15/ 14) and 
TP/T ( 37/ 34), but LP/T cost more than TP/T ( 22/ 19). 
Thus, irrespective of country and duration of treatment, the 
least expensive drug combination overall was TP/T followed 
by BP/T or LP/T, depending on the country.
Discussion
Our analysis shows that daily and annual costs of both TP 
and TP/T, after taking account of product shelf-life, were 
less than those of all corresponding glaucoma products in 
all four countries studied.
Our findings differ from those of Frenkel et al who 
considered that glaucoma products could be used until a 
bottle is empty.20 The latter study was performed in the US, 
where the healthcare environment and economic analytic 
methods differed from those of the present study, which 
followed European Summaries of Product Characteristics 
recommendations on product shelf-life following bottle 
opening. Obviously, their estimates would not apply to EU 
countries in which patients are advised to renew their medi-
cation when shelf-life is exceeded.
Lastly, their cost-effectiveness decision rule was based on 
average ratio, while incremental cost-effectiveness ratio is the 
estimate which is recommended by most health economics 
guidelines, leading to inefficient resource allocation. Also, 
IOP, a surrogate end-point of glaucoma progression, was 
used as an effectiveness parameter, although it is no more 
than a clinical trial efficacy parameter. Health authorities are 
not paying to reduce IOP, but to avoid blindness.
Drop-size has economic significance, too, which may be 
understood as follows. The conjunctival cul-de-sac normally 
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Figure 2 Latanoprost 0.005%: daily average of drop size and trend fitting.
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holds 7 to 9 µL of tears30,31 and contains a maximum fluid 
content of about 30 µL.30 Hence, an instillation volume of 
20 µL is usually considered adequate.32 In fact, the average 
drop-size in all countries studied always exceeded 20 µL, but 
only the first 20 µL would remain in the eye. Some of the 
remainder would be partially absorbed, with possible systemic 
effects, with the remainder coursing down the cheek and lead-
ing to possible skin effects. Nonetheless, a sufficient delivery 
of drug into the eye is assured. However, from bioavailability 
and toxicological points of view volumes 20 µL should be 
instilled.33–35 Moreover, smaller drop-sizes minimize waste 
and increase the number of drops available from bottles filled 
to a standard volume. Amongst monotherapy products TP 
bottles delivered the smallest drop sizes, as did TP/T amongst 
fixed combinations. Drop-size is determined by various 
factors, eg, design and physical characteristics of the dropper 
tip and bottle, physico-chemical properties of the solution, 
and the manner in which the patient dispenses drops.36
The methods we used to count drops were highly stan-
dardized in order to minimize the biases when comparing 
drop counts between brands. Therefore, it probably does 
not truly reflect the clinical reality of glaucoma patients and 
counts realized according to daily practice might be associ-
ated with higher variability. However, we think that the 
probability of getting contradictory results in daily practice 
might be low, when brand bottles look very similar. Drop 
counts collected with a medical device at the patient home 
would be required to confirm our findings.
All sampled eye-drop bottles provided sufficient drops for 
28 to 31 days of treatment, as required by the Summaries of 
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Figure 5 Latanoprost 0.005% + timolol: daily average of drop size and trend fitting.
Figure 4 Bimatoprost 0.03% + timolol: daily average of drop size by country and trend fitting.
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Product Characteristics. Extra drops were an assurance that 
the bottles could be used up to at least 28 or 31 days. Among 
monotherapy products, TP and BP provided greater surety 
than LP in all 4 countries. For fixed combination products, 
TP/T provided the greatest reserve in all 4 countries. Extra 
drops are important as older and some younger patients find 
it difficult to instill glaucoma drops and sometimes may miss 
entirely.37–39 In such situations TP and TP/T bottles provided 
the greatest reserve of drops, despite containing less fluid 
than their competitors.
The fact that for BP and BP/T we found different 
drop-counts between countries raises the question of 
cost generalizations between countries and suggests that 
purchasers might well conduct counts before reaching 
decisions. Also, parallel imports might not be neutral in terms 
of the number of drops provided.
Table 1 Daily drop-size (mg) by country of each drug
Drug Drug Country N Mean (SD) [Range]
PgA bimatoprost 0.03% Denmark 310 27.74 (0.943) [23.1–31.0]
Finland 310 28.28 (1.211) [25.9–34.4]
germany 310 28.31 (0.929) [25.9–31.2]
sweden 310 28.20 (0.842) [23.1–30.8]
latanoprost 0.005% Denmark 310 29.99 (3.158) [21.9–48.0]
Finland 310 29.75 (3.373) [20.0–48.9]
germany 310 29.86 (2.931) [22.9–49.1]
sweden 310 29.70 (3.002) [22.5–49.0]
travoprost 0.004% Denmark 310 25.87 (1.415) [20.6–32.6]
Finland 248 25.04 (1.756) [17.6–28.6]
germany 310 26.06 (2.168) [15.5–33.9]
sweden 310 24.58 (1.857) [19.4–32.1]
PgA/timolol bimatoprost 0.03% + timolol Denmark 310 29.22 (1.100) [25.3–33.2]
Finland 310 28.49 (1.017) [25.2–31.4]
germany 310 29.08 (1.308) [22.9–35.4]
sweden 310 29.33 (0.995) [25.3–32.8]
latanoprost 0.005% + timolol Denmark 310 30.18 (2.52) [12.6–50.8]
Finland 310 30.54 (2.692) [20.6–46.1]
germany 310 30.42 (2.803) [21.8–46.5]
sweden 310 30.22 (3.326) [20.2–53.9]
Denmark 310 25.79 (1.313) [21.8–29.4]
travoprost 0.004% + timolol Finland 310 25.54 (1.567) [18.9–28.9]
germany 310 25.85 (1.329) [20.6–30.2]
sweden 310 24.57 (1.694) [18.3–28.7]
Abbreviations: n, number of weighted drops; PgA, prostaglandin analogue; sD, standard deviation.
Figure 6 Travoprost 0.004% + timolol: daily average of drop size and trend fitting.
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Of course, pharmaceutical savings are not sufficient 
when considering treatment costs and must be set in the con-
text of effectiveness. In this respect, a recent meta-analysis by 
Denis et al19 showed that monotherapy with 2 recent PGAs 
(TP and BP) were more effective than LP in controlling 
IOP. According to data in the UK GPRD, the probability 
of no treatment switch with TP as first-line treatment was 
69.5% after 1 year.40 On applying the IRR (1.17), measured 
by Denis et al19 the probability of no treatment switches 
with LP as first-line treatment was 59.4%, about 10% more 
than with TP. Therefore, costs generated by more frequent 
treatment switches41 must be added to the higher price of LP. 
Consequently, in the present 4 European countries, TP would 
better control IOP at a lower treatment cost.
A similar conclusion may be drawn for second-line 
fixed combination treatments. According to Denis et al42 
the probability of a treatment switch with TP/T instillations 
is less than for LP/T. Consequently, patients treated 
with the first-line/second-line sequence TP/TP/T would 
experience fewer treatment failures than those treated 
with the LP/LP/T sequence. At 60 months TP used as the 
first-line prostaglandin followed by TP/T as the second-line 
treatment would avoid one third-line prescription in every 
11 incident cases. Since, in the present 4 countries, TP 
and TP/T drug costs were less than those of LP and LP/T, 
respectively, the former drug sequence would provide a 
better IOP control at a lower treatment cost. A full cost-
effectiveness analysis needs to be conducted to confirm 
these hypotheses.
Our survey suffers from several limitations. First, we 
purchased only a maximum of 5 bottles in each country from 
a single selected pharmacy, hence national extrapolation 
is questionable. Second, we assumed that our procedure 
mimicked the patients’ mode of instillation. Our standardized 
Table 2 Prostaglandin analogue monotherapy bottle contents and costs (euros) for Denmark
Bimatoprost 0.03% (BP) Latanoprost 0.005% (LP) Travoprost 0.004% (TP)
Total fill (g) 3.22 ± 0.09 3.01 ± 0.02 2.63 ± 0.01
[Range] [3.09–3.31] [2.99–3.04] [2.63–2.65]
number of drops 104 ± 2 79 ± 2 94 ± 5
[Range] [102–107] [75–80] [90–101]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after 
monthly treatment (31/28 days)
41%/46% 21%/29% 34%/41%
Product public price 20.95 24.36 20.94
Annual cost (31 days) 247 287 247
Daily cost (31 days) 0.676 0.786 0.675
Annual cost (28 days) 273 318 273
Daily cost (28 days) 0.748 0.870 0.748
Table 3 Prostaglandin analogue monotherapy bottle contents and costs (euros) for Finland
Bimatoprost 0.03% (BP) Latanoprost 0.005% (LP) Travoprost 0.004% (TP)
Total fill (g) 3.31 ± 0.08 3.00 ± 0.02 2.74 ± 0.01
[Range] [3.249–3.43] [2.97–3.02] [2.73–2.74]
number of drops 103 ± 4 79 ± 3 104 ± 11
[Range] [98–109] [74–82] [93–116]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
40%/45% 21%/29% 41%/46%
Product public price 24.97 24.97 24.11
Annual cost (31 days) 294 294 284
Daily cost (31 days) 0.805 0.805 0.778
Annual cost (28 days) 326 326 314
Daily cost (28 days) 0.892 0.892 0.861Clinical Ophthalmology 2009:3 478
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Table 4 Prostaglandin analogue monotherapy bottle contents and costs (euros) for germany
Bimatoprost 0.03% (BP) Latanoprost 0.005% (LP) Travoprost 0.004% (TP)
Total fill (g) 3.22 ± 0.09 3.01 ± 0.02 2.68 ± 0.01
[Range] [3.09–3.31] [2.99–3.04] [2.66–2.69]
Drop-count 103 ± 3 79 ± 4 92 ± 4
[Range] [98–106] [73–82] [89–99]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
40%/45% 22%/29% 33%/39%
Product public price 30.61 31.61 29.88
Annual cost (31 days) 360 372 352
Daily cost (31 days) 0.987 1.020 0.964
Annual cost (28 days) 399 412 390
Daily cost (28 days) 1.093 1.129 1.067
Table 5 Prostaglandin analogue monotherapy bottle contents and costs (euros) for sweden
Bimatoprost 0.03% (BP) Latanoprost 0.005% (LP) Travoprost 0.004% (TP)
Total fill (g) 3.22 ± 0.05 3.00 ± 0.03 2.82 ± 0.15
[Range] [3.18–3.28] [2.96–3.03] [2.71–2.99]
number of drops 103 ± 2 79 ± 2 115 ± 10
[Range] [100–105] [77–81] [102–128]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
40%/45% 21%/29% 46%/51%
Product public price 21.77 21.77 20.93
Annual cost (31 days) 256 256 246
Daily cost (31 days) 0.702 0.702 0.675
Annual cost (28 days) 284 284 273
Daily cost (28 days) 0.778 0.778 0.748
Table 6 Prostaglandin analogue/timolol fixed combination bottle contents and costs (euros) for Denmark
Bimatoprost 0.03%/timolol BP/T Latanoprost 0.005%/timolol LP/T Travoprost 0.004%/timolol TP/T
Total fill (g) 3.28 ± 0.09 3.03 ± 0.05 2.87 ± 0.01
[Range] [3.20–3.41] [2.98–3.07] [2.86–2.88]
number of drops 102 ± 3 82 ± 1 104 ± 5
[Range] [99–106] [81–83] [99–112]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after 
monthly treatment (31/28 days)
39%/45% 24%/32% 41%/46%
Product public price 30.46 29.29 27.64
Annual cost (31 days) 359 345 325
Daily cost (31 days) 0.982 0.945 0.892
Annual cost (28 days) 397 382 360
Daily cost (28 days) 1.088 1.046 0.987Clinical Ophthalmology 2009:3 479
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Table 8 Prostaglandin analogue timolol fixed combination bottle contents and costs (euros) for Germany
Bimatoprost 0.03%/timolol BP/T Latanoprost 0.005%/timolol LP/T Travoprost 0.004%/timolol TP/T
Total fill (g) 3.49 ± 0.06 3.03 ± 0.02 2.85 ± 0.02
[Range] [3.43–3.58] [3.01–3.05] [2.82–2.86]
number of drops 105 ± 3 80 ± 1 108 ± 6
[Range] [100–108] [78–82] [100–116]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
41%/47% 24%/30% 42%/48%
Product public price 33.18 34.12 31.17
Annual cost (31 days) 391 402 367
Daily cost (31 days) 1.070 1.101 1.005
Annual cost (28 days) 433 445 406
Daily cost (28 days) 1.185 1.219 1.113
Table 7 Prostaglandin analogue/timolol fixed combination bottle contents and costs (euros) for Finland
Bimatoprost 0.03%/timolol BP/T Latanoprost 0.005%/timolol LP/T Travoprost 0.004%/timolol TP/T
Total fill (g) 3.36 ± 0.04 3.01 ± 0.01 2.83 ± 0.01
[Range] [3.32–3.42] [3.00–3.03] [2.82–2.84]
number of drops 107 ± 2 79 ± 1 107 ± 10
[Range] [104–110] [78–80] [97–124]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
42%/47% 22%/29% 42%/47%
Product public price 30.73 30.73 29.85
Annual cost (31 days) 362 362 351
Daily cost (31 days) 0.991 0.991 0.963
Annual cost (28 days) 401 401 389
Daily cost (28 days) 1.098 1.098 1.066
Table 9 Prostaglandin analogue/timolol fixed combination bottle contents and costs (euros) for Sweden
Bimatoprost 0.03%/timolol BP/T Latanoprost 0.005%/timolol LP/T Travoprost 0.004%/timolol TP/T
Total fill (g) 3.29 ± 0.04 3.03 ± 0.03 2.83 ± 0.02
[Range] [3.22–3.34] [2.99–3.06] [2.81–2.85]
number of drops 102 ± 3 80 ± 1 115 ± 9
[Range] [98–104] [79–81] [102–125]
no. days treatment per month 31/28 31/28 31/28
% drops remaining after monthly 
treatment (31/28 days)
39%/45% 23%/30% 46%/51%
Product public price 25.50 28.96 25.50
Annual cost (31 days) 300 341 300
Daily cost (31 days) 0.823 0.934 0.823
Annual cost (28 days) 332 378 332
Daily cost (28 days) 0.911 1.034 0.911Clinical Ophthalmology 2009:3 480
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methodology, however, allowed us to obtain unbiased 
drop-counts from all bottles. Nonetheless, we recognize 
that real life instillation practices vary widely and that the 
drop-size ranges we used are probably under-estimated. Third, 
the evaluation was not ‘blinded’, ie, the investigator knew 
the treatment in each bottle. However, our measurements 
were objective and our procedures standardized, reproducible 
and validated. Fourth, we used only direct drug costs 
when claiming for lower cost, other costs were not taken 
into account. Hence, our survey is preliminary and a full 
evaluation is under investigation. On the other hand, from 
a societal point of view, costs are known to increase with 
accumulating treatment failures.41 Hence, the cost differences 
reported in this paper represent a conservative estimate 
of the true differences. Fifth, no sensitivity analysis was 
performed for potential wasted drops, ie, missed instillations 
and monthly extra drops used in real life. These associated 
costs, however, may be extrapolated directly from the tables. 
Lastly, we did not account for patient compliance which is 
known to be rather poor in glaucoma treatment.43,44 This 
could affect the number of days within a bottle, especially 
if patients do not account for the expiratory date.
Conclusions
In Denmark, Finland, Germany and Sweden, eye-drop 
bottles of travoprost 0.004% ± timolol incurred the lowest 
annual treatment costs, while providing sufficient surplus 
to compensate for potential fluid wastage from missed 
instillations, when compared to bimatoprost 0.03% ± timolol 
and latanoprost 0.005% ± timolol.
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